Gainers & Losers Of The Day: PULM, FWP, TNDM, ADHD, CNCE.

Alcobra Ltd.'s (ADHD) second phase III clinical trial of investigational product Metadoxine Extended Release (MDX) for the treatment of ADHD in adult patients did not meet the primary endpoint.

from RTT - Biotech http://ift.tt/2jXhtaH
via IFTTT